Gastric Neuroendocrine Tumors market Forecast. DelveInsight's Gastric Neuroendocrine Tumors Market report offers an in-depth understanding of the epidemiol ...
On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...
The symptoms of pancreatic cancer can be nonspecific, which means identifying the disease is often a challenge.
The EC approval of these two indications is based on results from the LITESPARK-004 and LITESPARK-005 trials, respectively, ...
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...
Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...
The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.
Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...
Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback